Utah Medical Products, Inc. (UTMD)
After hours:
| Previous Close | 66.29 |
| Open | 67.03 |
| Bid | 65.51 x 100 |
| Ask | 66.03 x 100 |
| Day's Range | 65.92 - 67.13 |
| 52 Week Range | 65.91 - 100.59 |
| Volume | |
| Avg. Volume | 31,042 |
| Market Cap | 236.588M |
| Beta (5Y Monthly) | 0.13 |
| PE Ratio (TTM) | 14.42 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.20 (1.82%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
- ACCESSWIRE
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2024
SALT LAKE CITY, UT / ACCESSWIRE / April 25, 2024 / In the first calendar quarter (1Q) of 2024, Utah Medical Products, Inc. (NASDAQ:UTMD) attained financial results consistent with its previously announced projections for calendar year 2024. Summary ...
- GlobeNewswire
UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance
SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial results for the full year of 2023 consistent with management’s beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amo
- GlobeNewswire
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023
SALT LAKE CITY, UT, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this re
